What is AbCellera?
AbCellera is a biotechnology firm headquartered in Vancouver, Canada, dedicated to the discovery and development of therapeutic antibodies. The company employs a proprietary technology platform that integrates single-cell screening, machine learning, and high-throughput genomics to expedite the identification and advancement of novel antibody-based medicines. AbCellera actively partners with leading pharmaceutical and biotechnology organizations to accelerate the development pipeline for treatments targeting critical areas such as oncology, autoimmune disorders, and infectious diseases. The company's approach is designed to significantly reduce the time and cost associated with bringing new antibody therapies to market.
How much funding has AbCellera raised?
AbCellera has raised a total of $886.5M across 4 funding rounds:
Series A
$10M
Series B
$105M
Stock Offering
$483M
Stock Offering
$288.5M
Series A (2018): $10M with participation from DCVC Bio
Series B (2020): $105M led by Viking Global Investors, OrbiMed Advisors LLC, Peter Thiel, University of Minnesota, Eli Lilly and Company, Founders Fund, Presight Capital, and DCVC Bio
Stock Issuance/Offering (2020): $483M supported by Undisclosed
Stock Issuance/Offering (2021): $288.5M, investors not publicly disclosed
Key Investors in AbCellera
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
OrbiMed Advisors LLC
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies, sectors and stages. The firm's partners have been founders and early funders of companies including PayPal, SpaceX, Palantir, Anduril, Airbnb, Stripe and Facebook.
What's next for AbCellera?
With the recent influx of major strategic investment, AbCellera is poised to further enhance its proprietary technology platform and expand its collaborative efforts. This significant capital backing is expected to accelerate the company's research and development initiatives, potentially leading to the advancement of new antibody-based therapeutics through clinical trials. The company's focus on leveraging advanced technology for antibody discovery positions it for continued leadership and innovation in the biopharmaceutical landscape, aiming to address unmet medical needs across a spectrum of diseases.
See full AbCellera company page
